Massive RSV vaccine trial aims to slash hospitalizations in adults
NCT ID NCT06684743
First seen Jan 11, 2026 · Last updated Jun 13, 2026 · Updated 23 times
Summary
This large study tests whether the Abrysvo RSV vaccine can prevent hospitalizations due to RSV in adults aged 18 and older. About 690,000 participants are randomly assigned to receive either the vaccine or no vaccine. The main goal is to see if the vaccine reduces the number of people hospitalized for RSV-related breathing problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Translational Cardiology and Pragmatic Randomized Trials Department of Cardiology Copenhagen University Hospital - Herlev and Gentofte
Copenhagen, 2900, Denmark
-
Danske Lægers Vaccinations Service
Søborg, 2860, Denmark
-
General Public Health Directorate of Galician Health Service
Santiago de Compostela, A Coruña, Spain
Conditions
Explore the condition pages connected to this study.